Migralaxis Tablet SR is a unique combination product containing Propranolol (40mg) and Flunarizine (10mg) in a sustained-release formulation. This product is indicated for the prophylactic treatment of migraines, as well as for the prevention of cluster headaches and other forms of vascular headache. The Propranolol component contributes to the product's anti-migraine properties, while the Flunarizine component helps to reduce the frequency and severity of migraine attacks. The sustained-release formulation ensures a gradual release of the active ingredients over an extended period, providing a prolonged therapeutic effect. Migralaxis Tablet SR is administered orally, usually once or twice daily, depending on the individual patient's response and the severity of their condition. The product is contraindicated in patients with known hypersensitivity to either Propranolol or Flunarizine, and caution is advised in patients with a history of depression, congestive heart failure, or peripheral artery disease. As with all medications, Migralaxis Tablet SR should be used under the guidance of a healthcare professional and in accordance with the product's official prescribing information.